Mineralys officer plans $217K stock sale

Available on EDGAR 09/14/2026 - 04:07 PM EDT Accepted by SEC EDGAR 09/14/2026 - 04:06 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. (MLYS) disclosed that an officer, David Rodman, has filed a notice under Rule 144 to sell up to 7,709 shares of common stock, with an aggregate market value of $216,931.26, when 88,406,885 shares were outstanding on the planned sale date.

The planned sale on 09/14/2026 is tied to the exercise of employee stock options via a broker-assisted cashless exercise. The filing also lists multiple prior common stock sales by Rodman over the past three months, each with specified share amounts and dollar values.

Key Figures

Shares to be sold under Rule 144: 7,709 shares Aggregate market value of planned sale: $216,931.26 Shares outstanding: 88,406,885 shares +3 more

6 metrics

Shares to be sold under Rule 144 7,709 shares Planned sale of common stock on 09/14/2026

Aggregate market value of planned sale $216,931.26 Value of 7,709 shares to be sold

Shares outstanding 88,406,885 shares Common stock outstanding as referenced with the planned sale date

Past sale on 06/12/2026 6,349 shares for $151,901.37 Common stock sold by David Rodman during the past three months

Past sale on 06/15/2026 9,890 shares for $235,487.24 Common stock sold by David Rodman during the past three months

Past sale on 09/09/2026 2,171 shares for $67,018.77 Most recent common stock sale listed for David Rodman

Key Terms

Rule 144, cashless exercise, aggregate market value, broker assisted

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

cashless exercise financial

"Broker assisted with cashless exercise"

A cashless exercise is a way for an option holder to convert stock options into actual shares without paying the purchase price in cash; instead they immediately give up a portion of the newly issued shares to cover the cost and any withholding taxes. Investors care because this process increases the number of shares available and can slightly dilute existing holdings, while also signaling how insiders or employees are realizing compensation without needing cash — similar to paying for a purchase by handing over part of what you just bought.

aggregate market value financial

"7709 | 216931.26 | 88406885 | 09/14/2026"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

broker assisted financial

"Broker assisted with cashless exercise"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for Mineralys Therapeutics (MLYS)?

The filing states that officer David Rodman intends to sell up to 7,709 shares of Mineralys Therapeutics common stock under Rule 144, relating to the exercise of employee stock options through a broker-assisted cashless exercise on 09/14/2026.

How many Mineralys Therapeutics (MLYS) shares are covered by this planned Rule 144 sale?

The notice covers up to 7,709 shares of Mineralys Therapeutics common stock, with an aggregate market value of $216,931.26 as reflected in the filing’s securities information section.

How many Mineralys Therapeutics (MLYS) shares were outstanding at the time referenced in the filing?

The filing reports that 88,406,885 shares of Mineralys Therapeutics common stock were outstanding as of the date referenced with the planned 09/14/2026 Rule 144 sale.

What recent sales by David Rodman are disclosed in the Form 144 for MLYS?

The document lists several past three‑month sales, including 6,349 shares on 06/12/2026 for $151,901.37 and 9,890 shares on 06/15/2026 for $235,487.24, along with additional specified transactions through 09/09/2026.

How will the Mineralys Therapeutics (MLYS) Rule 144 sale be executed?

The planned sale of 7,709 shares is described as a broker assisted with cashless exercise of employee stock options, using Merrill Lynch as the broker, according to the securities to be sold section.

Who is the person for whose account Mineralys Therapeutics (MLYS) securities will be sold?

The notice identifies David Rodman as the person for whose account the securities are to be sold and notes his status as an officer of Mineralys Therapeutics, Inc.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001672659
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Mineralys Therapeutics, Inc.
SEC File Number	001-41614
Address of Issuer	150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PENNSYLVANIA 19087
Phone	(888) 378-6240
Name of Person for Whose Account the Securities are To Be Sold	Rodman David Malcom
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	7709	216931.26	88406885	09/14/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	09/14/2026	Exercise of employee stock options	Mineralys Therapeutics, Inc.			7709	09/14/2026	Broker assisted with cashless exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	06/12/2026	6349	151901.37
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	06/15/2026	9890	235487.24
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	06/17/2026	4584	114600.00
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	07/09/2026	2171	65781.30
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	07/13/2026	14058	387716.51
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	07/15/2026	6349	168954.55
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	07/17/2026	416	11016.30
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	08/10/2026	2170	58785.30
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	08/13/2026	14056	372187.00
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	08/17/2026	417	10616.82
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	09/09/2026	2171	67018.77

144: Remarks and Signature

Remarks
Date of Notice	09/14/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/29/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	David Rodman
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)